What is CJC-1295 (no DAC)?
CJC-1295 without DAC, also known as Mod GRF 1-29 or Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). It consists of the first 29 amino acids of GHRH with four amino acid substitutions that improve stability and half-life.
Important distinction: CJC-1295 exists in two forms:
- CJC-1295 no DAC (Mod GRF 1-29): Shorter half-life (~30 minutes), pulsatile release
- CJC-1295 with DAC: Drug Affinity Complex extends half-life to ~8 days, continuous release
This guide covers the no DAC version, which is more commonly used in research due to its ability to maintain natural pulsatile GH patterns.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 2mg |
| Recommended BAC Water | 2.5mL |
| Resulting Concentration | 2mg/mL (2000mcg/mL) |
| Typical Research Dose | 100-300mcg |
| Frequency | 2-3x daily |
| Half-life | ~30 minutes |
| Research Duration | 8-16 weeks |
Reconstitution Guide
Materials Needed
- CJC-1295 (no DAC) 2mg lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (U-100, 29-31 gauge)
- Alcohol swabs
- Sharps container
Step-by-Step Instructions
-
Prepare workspace — Clean area, gather all materials, wash hands.
-
Clean vial stoppers — Alcohol swab both vials. Allow to dry.
-
Draw BAC water — Draw 2.5mL bacteriostatic water into syringe.
-
Add to peptide — Inject slowly down inside wall of vial. Avoid direct contact with powder.
-
Dissolve — Allow 2-3 minutes for dissolution. Gentle swirl if needed.
-
Verify — Solution should be completely clear.
-
Label and store — Date vial and refrigerate immediately.
Note: CJC-1295 no DAC is more fragile than some peptides — handle carefully and use within 2-3 weeks of reconstitution.
Dosage Protocol
Concentration Calculations
With 2mg peptide in 2.5mL BAC water:
- Concentration: 2mg/mL = 2000mcg/mL
- Per unit (U-100 syringe): 20mcg per unit
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 100mcg | 0.05mL | 5 units |
| 150mcg | 0.075mL | 7.5 units |
| 200mcg | 0.10mL | 10 units |
| 300mcg | 0.15mL | 15 units |
Suggested Research Protocols
Standalone Protocol:
- Dose: 100-200mcg
- Frequency: 2-3x daily
- Timing: Morning, post-workout, bedtime
- Duration: 12-16 weeks
Combined Protocol (with Ipamorelin):
- CJC-1295 no DAC: 100mcg
- Ipamorelin: 200mcg
- Frequency: 2-3x daily
- Duration: 12-16 weeks
- Note: GHRH + GHRP synergy
Timing Optimization
| Administration | Rationale |
|---|---|
| Morning (fasted) | Low insulin enhances response |
| Post-exercise | Exercise-induced GH synergy |
| Before bed | Augments natural sleep GH pulse |
Avoid: Administering within 2 hours of meals
Injection Guide
Subcutaneous Administration
- Clean injection site with alcohol
- Pinch skin at abdomen, thigh, or arm
- Insert needle at 45-90° angle
- Inject slowly and steadily
- Wait 5 seconds before withdrawing
Site Rotation
Standard rotation:
- Abdomen (most common)
- Outer thigh
- Back of upper arm
Storage Requirements
Lyophilized (Powder)
- Temperature: -20°C (-4°F) or colder
- Duration: 2+ years
- Conditions: Dry, dark, airtight
Reconstituted
- Temperature: 2-8°C (36-46°F)
- Duration: 2-3 weeks (shorter than some peptides)
- Conditions: Refrigerated, protected from light
Important: CJC-1295 no DAC has a shorter reconstituted stability than many peptides. Use within 2-3 weeks.
Research Considerations
Mechanism of Action
CJC-1295 no DAC works through:
- GHRH receptor activation: Stimulates pituitary somatotrophs
- Pulsatile GH release: Short half-life creates distinct pulses
- Preserved feedback: Maintains physiological regulation
- IGF-1 elevation: Secondary to GH increase
No DAC vs With DAC
| Aspect | No DAC (Mod GRF 1-29) | With DAC |
|---|---|---|
| Half-life | ~30 minutes | ~8 days |
| GH pattern | Pulsatile | Elevated baseline |
| Dosing | 2-3x daily | 1-2x weekly |
| Feedback | Preserved | May be altered |
| Research use | More common | Less common |
Synergy with GHRPs
The combination of GHRH (CJC-1295) + GHRP (Ipamorelin) produces synergistic effects:
- GHRH primes the pituitary
- GHRP amplifies the release
- Combined response > sum of individual responses
- Research shows 2-3x amplification
Saturation Considerations
Research suggests:
- 100mcg may approach saturation per dose
- Higher single doses show diminishing returns
- Multiple daily doses more effective than single large dose
- Individual response varies significantly
Common Combinations
CJC-1295 no DAC + Ipamorelin: Most popular research combination. Clean GH release profile.
CJC-1295 no DAC + GHRP-2: Stronger GH release but increased hunger/cortisol.
CJC-1295 no DAC + GHRP-6: Potent combination with significant appetite stimulation.
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.
Scientific References
- Alba M, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab. 2006;291:E1290-E1294.
- Ionescu M, Bhaumick B. “GHRH analogs: current and future perspectives.” Mol Cell Endocrinol. 2002;197:75-81.
- Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.” J Clin Endocrinol Metab. 2006;91:799-805.
Last updated: December 01, 2024
Disclaimer: This information is for educational and research purposes only. CJC-1295 is a research chemical not intended for human consumption. Always follow applicable laws and institutional guidelines.